Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Autor: Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou

Publikováno v: Thoracic Cancer, Vol 15, Iss 5, Pp 419-426 (2024)

Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and

Externí odkaz: https://doaj.org/article/5593cfcf22cf4de189ad661dbe843899

Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy

Autor: Elaine Lai-Han Leung, Run-Ze Li, Xing-Xing Fan, Lily Yan Wang, Yan Wang, Zebo Jiang, Jumin Huang, Hu-Dan Pan, Yue Fan, Hongmei Xu, Feng Wang, Haopeng Rui, Piu Wong, Hermi Sumatoh, Michael Fehlings, Alessandra Nardin, Paul Gavine, Longen Zhou, Yabing Cao, Liang Liu

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)

Abstract Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung

Externí odkaz: https://doaj.org/article/c845ab00de49468c83ac80f41f9fb0d6

SIGNIFICANCE OF PLASMA TGF-β1 LEVEL DETECTION IN PATIENTS WITH T2DM WITH HEART FAILURE.

Autor: Yunjing Sun, Bo Miao, Yabing Cao, Jiangman Cui, Yingxiao Da, Liping Qi, Song Zhou

Publikováno v: Journal of Medical Biochemistry; 2024, Vol. 43 Issue 5, p704-710, 7p

Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma

Autor: Yabing Cao, Kin Iong Chan, Gungli Xiao, Yanqun Chen, Xibin Qiu, Hu Hao, Sao Chi Mak, Tongyu Lin

Publikováno v: BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)

Abstract Background The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study we investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry a

Externí odkaz: https://doaj.org/article/2fd029584ca04c1b9212c4ba894a1b26

Identification of the SERK Gene Family in Paulownia fortunei and Its Involvement in the Response to Biotic and Abiotic Stresses.

Autor: Tongman Zhao, Yujie Fan, Yabing Cao, Xiaogai Zhao, Guoqiang Fan

Publikováno v: Phyton (0031-9457); 2023, Vol. 92 Issue 9, p2473-2488, 16p